Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 34fludarabine 25fludarabine phosphate 24Tacrolimus 24Mycophenolic Acid 23Whole-Body Irradiation 22Busulfan 15Methotrexate 12Melphalan 12Granulocyte Colony-Stimulating Factor 12Antilymphocyte Serum 12thymoglobulin 11Cyclosporine 11Stem Cell Transplantation 10Filgrastim 10Rituximab 9Thiotepa 7Peripheral Blood Stem Cell Transplantation 7Nivolumab 7Dexamethasone 7trametinib 6Radiotherapy 6Mesna 6Cytarabine 6Prednisone 5Calcium Dobesilate 5Bortezomib 5Azacitidine 5Alemtuzumab 5Voriconazole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hematologic Neoplasms × INCB059872 × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡